Xandar Kardian

About Xandar Kardian

Xandar Kardian operates at the intersection of healthcare technology and smart building management, utilizing proprietary radar signal processing to deliver autonomous monitoring solutions. The company, a US Delaware C-Corp, was formally incorporated in 2017 with a mission to deploy high-accuracy health and building automation systems globally. Its research and development efforts trace back to 2011, originating from a university lab project focused on the applications of radar technology. The company is led by co-founder and CEO Sam Yang, a serial entrepreneur with over two decades of experience in the tech and healthcare sectors, who previously founded companies like Kairos Watches, which pioneered hybrid smartwatches. He is joined by co-founders David Kim and Sung Ho Cho. Headquartered in Toronto, Canada, Xandar Kardian maintains a significant R&D presence in South Korea and offices in the United States.

The firm's core business revolves around two main verticals: healthcare and real estate technology. In the healthcare sector, Xandar Kardian targets hospitals, long-term care facilities (including skilled nursing, assisted living, and memory care), and home health monitoring providers. The business model involves the sale and deployment of its monitoring systems, which may qualify for Medicare/Medicaid reimbursement under specific CPT codes for patients with chronic respiratory or cardiovascular disorders. For the smart building market, the company provides real-time occupancy data to commercial and public building operators, enabling advanced energy optimization for HVAC and lighting systems, which presents a more effective alternative to traditional passive infrared (PIR) sensors.

Xandar Kardian's flagship product is the XK300 Autonomous Health Monitoring Solution. This system employs ultra-wideband (UWB) impulse radar to continuously and contactlessly measure vital signs, including resting heart rate and respiratory rate, as well as body motion and presence. The technology works by detecting micro-vibrational patterns emitted by the human body, capable of penetrating materials like blankets and clothing from a distance. A key milestone was achieved in April 2021 when the XK300 received FDA 510(k) clearance as a Class II medical device, validating its use for both adult and infant patients in hospital, nursing home, and residential settings. This clearance allows the system to be marketed for providing early deterioration detection by autonomously tracking vital sign trends and alerting medical staff to potential issues. The company has secured significant funding, including a $10 million Series A round in December 2021, to fuel commercial rollout and further R&D.